Filana Therapeutics (FLNA) Enterprise Value (2010 - 2026)

Filana Therapeutics has reported Enterprise Value for 17 years, with the latest figure at -$25.2 million in Q2 2026.

• On a quarterly basis, Enterprise Value fell 1.01% year-over-year to -$25.2 million in Q2 2026; TTM through Jun 2026 was -$25.2 million, a 1.01% decrease from a year earlier, with the FY2025 full-year figure at $147635.0, up 101.0% from the prior year.
• Enterprise Value was -$25.2 million for Q2 2026 at Filana Therapeutics, down from -$4.9 million in the prior quarter.
• The five-year high for Enterprise Value was $1.5 billion in Q3 2022, with the low at -$44.9 million in Q1 2025.
• Average Enterprise Value over 5 years is $560.5 million, with a median of $656.0 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 118.9% in 2024, then tumbled 106.48% in 2025.
• Over 5 years, Enterprise Value stood at $1.0 billion in 2022, then retreated by 19.6% to $829.6 million in 2023, then plunged by 101.79% to -$14.8 million in 2024, then soared by 101.0% to $147635.0 in 2025, then tumbled by 17165.47% to -$25.2 million in 2026.
• The last three Enterprise Value figures came in at -$25.2 million (Q2 2026), -$4.9 million (Q1 2026), and $147635.0 (Q4 2025), per Business Quant data.